Non-diabetic chronic kidney disease – prevention and treatment on the basis of AIPRI Study results Review article
Article Sidebar
Published:
Mar 31, 2011
Keywords:
chronic kidney disease, epidemiology, recognition, treatment, benazepril
Main Article Content
Abstract
The paper presents classification, epidemiology and basic diagnostic methods of chronic kidney disease (CKD) which is regarded as another civilization disease. Simultaneously possibilities of prevention and treatment of non-diabetic CKD were discussed. Inhibition of the renin-angiotensin-aldosteron system with angiotensin-converting-enzyme inhibitors (ACEi) plays fundamental role in the management of this condition. Use of ACEi is considered as cornerstone strategy among patients with non-diabetic CKD and proteinuria. The AIPRI Study results confirmed that pharmacological treatment with ACEi – benazepril in this group of patients allows significantly reduce the risk of end-stage renal disease and the need of renal replacement therapy.
Article Details
How to Cite
Grabysa , R. (2011). Non-diabetic chronic kidney disease – prevention and treatment on the basis of AIPRI Study results. Medycyna Faktow (J EBM), 4(1(10), 83-90. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2554
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Rutkowski B.: Przewlekła choroba nerek (PChN) – wyzwanie XXI wieku. Przewodnik Lekarski 2007; 2(94): 80-87.
2. Król E., Czarniak P., Rutkowski B. et al.: Early detection of chronic kidney disease: results of the PolNef study. Am. J. Nephrol. 2008; 29: 264-73.
3. Król E., Rutkowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
4. NKF K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39(2, supl. 1): S1-S266.
5. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
6. Stevens L.A., Levey A.S.: Current status and future perspectives for CKD testing. Am. J. Kidney Dis. 2009; 53(3 Suppl. 3): S17-S26.
7. Zhang Q.I., Rothenbacher D.: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117.
8. Coresh J., Selvin E., Stevens L.A. et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007; 17: 2038-47.
9. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
10. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
11. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
12. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
13. Hallan S.I., Ritz E., Lydersen S. et al.: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 2009; 20: 1069-77.
14. Cockroft D.W., Gault M.H.: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Levey A.S., Bosch J.P., Lewis J.B. et al.: for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999; 130: 461-70.
16. Mancia G., De Backer G., Dominiczak A. et al.: Management of Arterial Hypertension of the European Society of Hypertension/European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. J. Hypertens. 2007; 25(6): 1105-1187.
17. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progresssion of chronic kidney disease. Kidney Int. Suppl. 2005; (99): S57-S65.
18. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
20. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-40.
22. Jafar T.H., Schmid C.H., Landa M. et al.: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Ann. Intern. Med. 2001; 135: 73-87.
23. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
24. Zasady postępowania w nadciśnieniu tętniczym – 2008 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tętnicze 2008; 12: supl.C.
25. Mann J.F., Schmieder R.E., McQueen M. et al.: Renal outcomes with telmisartan, ramipryl, or both, in people at high wascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-53.
2. Król E., Czarniak P., Rutkowski B. et al.: Early detection of chronic kidney disease: results of the PolNef study. Am. J. Nephrol. 2008; 29: 264-73.
3. Król E., Rutkowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1(1): 1-6.
4. NKF K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39(2, supl. 1): S1-S266.
5. Levey A.S., Eckhardt K.U., Tsukamoto Y. et al.: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
6. Stevens L.A., Levey A.S.: Current status and future perspectives for CKD testing. Am. J. Kidney Dis. 2009; 53(3 Suppl. 3): S17-S26.
7. Zhang Q.I., Rothenbacher D.: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117.
8. Coresh J., Selvin E., Stevens L.A. et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007; 17: 2038-47.
9. Fox C.S., Larson M.G., Leip E.P. et al.: Predictors of new-onset kidney disease in community-based population. JAMA 2004; 291: 844-50.
10. Wang Y., Chen X., Song Y. et al.: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008; 73: 19-33.
11. James M.T., Hammelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-309.
12. Go A.S., Chertow G.M., Fan D. et al.: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
13. Hallan S.I., Ritz E., Lydersen S. et al.: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 2009; 20: 1069-77.
14. Cockroft D.W., Gault M.H.: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Levey A.S., Bosch J.P., Lewis J.B. et al.: for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999; 130: 461-70.
16. Mancia G., De Backer G., Dominiczak A. et al.: Management of Arterial Hypertension of the European Society of Hypertension/European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. J. Hypertens. 2007; 25(6): 1105-1187.
17. Remuzzi G., Perico N., Mancia M. et al.: The role of renin-angiotensin-aldosterone system in the progresssion of chronic kidney disease. Kidney Int. Suppl. 2005; (99): S57-S65.
18. Brewster U.C., Perazella M.A.: The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004; 116: 263-72.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939-45.
20. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril in decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1957-63.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-40.
22. Jafar T.H., Schmid C.H., Landa M. et al.: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Ann. Intern. Med. 2001; 135: 73-87.
23. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
24. Zasady postępowania w nadciśnieniu tętniczym – 2008 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tętnicze 2008; 12: supl.C.
25. Mann J.F., Schmieder R.E., McQueen M. et al.: Renal outcomes with telmisartan, ramipryl, or both, in people at high wascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-53.